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When is an emergency department not an emergency department?
Editor—Recently, a young couple,
equipped with backpacks and bedrolls,
walked into our local accident and emer›
gency department at about 11 pm, climbed
into sleeping bags, and set their alarm clock.
Early next morning, roused by their alarm,
the couple rolled up their bags and left.
What was the explanation for this
behaviour?
It was not careful preparation for
attending a department in which the waiting
time can often be eight hours or more. The
young couple, who lived in Surrey, had
booked a holiday that started with a
morning flight from Stansted Airport.
Rather than get up at 4 am to get from Sur›
rey to Stansted, they had worked out that it
would be easier to spend the night nearer to
the airport, and that our emergency depart›
ment would be the safest (and cheapest)
place in which to do this.
This curious but true story may raise a
laugh, but it also raises a far more serious
problem: that of the current abuse and mis›
use of emergency services. Initiatives involv›
ing patient education or NHS Direct are
having minimal impact in stopping the pub›
lic using emergency departments inappro›
priately.1 Departments are still overrun by
patients with conditions that can be treated
in primary care, with the result that waiting
times remain lengthy and staff are subject to
abuse by tired and tetchy people.
Is it time to invert the knowledge
pyramid and put experienced doctors back
into primary decision making roles? An
emergency consultant, in partnership with
an experienced nurse, could effectively
triage (and weed out) patients at the first
point of contact. Only patients with a genu›
ine emergency would gain access.
Finally, in this era of rebranding, where
accountants become days of the week, steel
firms morph into male voice choirs, and the
president of Turkmenistan renames the
months of the year after himself and his
mother, we should perhaps follow the
American example and rename emergency
departments emergency rooms. Then put a
large legend on the door defining emer›
gency for each patient about to pass through
it: “An unforeseen occurrence or combina›
tion of circumstances that is potentially dan›
gerous and calls for immediate action.”2
Sue Collinson project officer
WHO Collaborating Centre for Research and
Training for Mental Health, Institute of Psychiatry,
London SE5 8AF
Trevor Turner consultant psychiatrist
East London and the City Mental Health NHS
Trust, Homerton Hospital, London E9 6SR
1 Munro J, Nicholl J, O’Cathain A, Knowles E. Impact of
NHS Direct on demand for immediate care: observational
study. BMJ 2000;321:150›3.
2 New Penguin English dictionary. Harmondsworth: Penguin,
2000:454.
Focus on emergency
departments to reduce delays
in thrombolysis
Editor—Qasim et al reported the safety and
efficacy of nurse initiated thrombolysis in
patients with acute myocardial infarction.1
The stepwise improvement in thrombolysis
times over the three phases is impressive
and a credit to the medical and nursing staff
of the coronary care unit. We hope that
phase 4 will continue to show improvement,
enabling the 2003 national service frame›
work targets to be met.
The emergency department gets merely
a cursory mention in the context of reasons
and causes of delays in treatment. It seemed
not to be deemed important in streamlining
the management of patients with acute
myocardial infarction. Yet during phase 1 it
was one of the “two main reasons” for delays
identified.
Phase 2 does not address this problem.
Patients with suspected acute myocardial
infarction in the emergency department
were transferred to the coronary care unit
for further assessment by a nurse. Presum›
ably the patient had already seen a doctor in
the department? Why not initiate treatment
there? The coronary care nurse still had to
call the on call medical team to see the
patient; this was identified as a source of
delay.
Phase 3 improved on this with nurse ini›
tiated thrombolysis, yet the patients coming
from the emergency department had
already been assessed. The diagnosis of a
barn door myocardial infarction is based on
the first electrocardiogram; if this is taken in
the emergency department why not treat
the patient there? The coronary care nurse
repeats the electrocardiography, which
again represents an unnecessary delay.
In our department we have a protocol
for the prompt assessment and treatment of
patients who attend with acute myocardial
infarction. All patients with chest pain are
triaged as red, have electrocardiography,
and are considered immediately for throm›
bolysis by the medical staff in the depart›
ment. Since all staff are fully aware of the
protocol and the urgency with which acute
myocardial infarction needs to be treated,
the operation runs smoothly. Our results are
frequently audited to identify and minimise
delays and inappropriate thrombolysis. In
the six months before April 2002 we gave
thrombolysis in 92 barn door myocardial
infarctions, 92% within 30 minutes and 85%
within 20 minutes.
We believe that an emergency depart›
ment is the most appropriate place for
patients with myocardial infarction to be
assessed and treated. Our methods have
proved that with training of staff and audit of
data the national framework targets are
achievable, with patients benefiting the most.
C J L Hetherington specialist registrar in emergency
medicine
P Doyle consultant in emergency medicine
J A Kayani consultant in emergency medicine
D F Gorman consultant in emergency medicine
Accident and Emergency Department, Selly Oak
Hospital, University Hospital Birmingham NHS
Trust, Birmingham B29 6JD
hethers@doctors.org.uk
1 Qasim A, Malpass K, O’Gorman DJ, Heber ME. Safety and
efficacy of nurse initiated thrombolysis in patients with
acute myocardial infarction. BMJ 2002;324:1328›31. (1
June.)
Probiotics and antibiotic
associated diarrhoea
Lactulose is effective
Editor—D’Souza et al evaluated potential
agents for the prevention of antibiotic asso›
ciated diarrhoea, whose full spectrum of
activity is immense both in the community
and in hospital.1 In particular, the antithera›
peutic default selection of Clostridium difficile
Advice to authors
We would like to receive all responses
electronically at our website. Please send your
letter directly to bmj.com as a rapid response to
a published article.
All rapid responses will be considered for
publication in the paper journal; authors will be
notified by email if their rapid response has been
accepted, but not otherwise.
For more detailed advice please see
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with resultant colitis is associated with a con›
siderable morbidity and mortality.
Alteration of the faecal flora is attractive
as a low risk means of preventing or,
possibly, treating C difficile and associated
infections.2 Induced disequilibrium of the
colonic flora can be achieved either through
supplemental probiotic loading or by thera›
peutic manipulation. Faecal flora can be
manipulated through the use of lactulose, a
synthetic disaccharide that is predominantly
used as an osmotic laxative. It is neither
absorbed nor metabolised in the upper
gastrointestinal tract but is degraded by the
bacterial flora of the proximal colon to
organic acids. These acidify the proximal
colon and result in a dose dependent
catharsis.
Lactulose has several additional proper›
ties, including an antiendotoxin effect and
alteration of faecal floral patterns.3 This
quantitative alteration in faecal floral pat›
terns, with an increase in faecal Lactobacillus
acidophilus and a reduction in both coliforms
and bacteroides, has been confirmed in our
own unpublished work. A qualitative altera›
tion in bacterial pathogenicity may result
with lactulose as an alternative substrate.
Additional historical evidence shows
effective treatment of shigellosis and salmo›
nellosis with lactulose.4 5 Several risk and
host factors have been recognised, and iden›
tification of people at high risk of antibiotic
associated diarrhoea could facilitate tar›
geted pretreatment with lactulose or con›
joint treatment with lactulose and antibiot›
ics. An effective means of gaining rapid
benefit might be through combining lactu›
lose with a probiotic such as L acidophilus.
Additionally, in people who have
developed antibiotic associated diarrhoea,
lactulose induced manipulation of the
faecal flora may prove to be an effective
means of treating the infective cause of the
diarrhoea, although clinicians may not eas›
ily be convinced to treat diarrhoea with a
laxative.
Mark Battle specialist registrar
Lara Teare senior house officer
Sue Law preregistration house officer
Jamie Fulton consultant
jamie.fulton@phnt.swest.nhs.uk
Directorate of Medicine, Derriford Hospital,
Plymouth PL6 8DH
1 D’Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in
prevention of antibiotic associated diarrhoea: meta›
analysis. BMJ 2002;324:1361›4. (8 June.)
2 Liehr H, Englisch G, Rasenack U. Lactulose—a drug with
anti›endotoxin effect. Hepato›gastroenterology 1980;27:
356›60,
3 Vince A, Zeegen R, Drinkwater JE, O’Grady F, Dawson AM.
The effect of lactulose on the faecal flora of patients with
hepatic encephalopathy. J Med Microbiol 1974;7:163›8.
4 Levine MM, Hornick RB. Lactulose therapy in Shigella
carrier state and acute dysentery. Antimicrob Agents
Chemother 1975;8:581›4.
5 Scevola D, Barbarini G, Concia E, Michelone G, Imo V.
Costs and benefits of diagnostic and therapeutic methods
in salmonella infections.Bolletttino dell Instituto Sieroterapico
Milanese 1985;64:376›80.
The case for probiotics remains unproved
Editor—We were surprised at the assertion
by D’Souza et al that probiotics may reduce
the incidence of antibiotic associated diar›
rhoea caused by Clostridium difficile.1 Only
10›25% of antibiotic associated diarrhoea is
caused by infection with C difficile, and infec›
tions are most commonly seen in elderly
people.
Only four of the studies analysed
included elderly patients (Gotz, Surawicz,
McFarland, and Lewis), and in only four
studies were any analyses for C difficile done
(Orrhage (normal volunteers, no cases
seen), Surawicz, McFarland, Lewis). Either
on their own or combining the results of
these studies shows no benefit from probiot›
ics (odds ratio 0.71, 95% confidence interval
0.29 to 1.76) (figure).
There are several rigorous systematic
reviews on the subject of probiotics and
diarrhoea, but the temptation to perform a
meta›analysis has been resisted because of
the lack of comparability of different
probiotic organisms. D’Souza et al recognise
this limitation when postulating the different
mechanisms of action for the yeast and bac›
terial probiotics.
The author’s principal inclusion cri›
terion was the occurrence of diarrhoea,
defined as two or more loose motions per
day for at least two days. Of the studies ana›
lysed only three met this criterion (Surawicz,
McFarland, and Vanderhoof).
There was an error in table 1, instead of
no cases of diarrhoea (Gotz et al) three cases
(8.3%) occurred in the active group. In the
study by Orrhage et al only half the
volunteers who received active treatment
were included, those not included had a
higher incidence of diarrhoea. It is not clear
why the prospective double blind placebo
controlled study by Borgia was excluded2;
yet a trial by Orrhage was included that was
principally a bacteriological study in healthy
adults.
Furthermore, a trial by Colombel et al
was excluded for being single blinded,
although it was a double blind placebo
controlled trial.3 Five studies were not
analysed on an intention to treat basis
(Surawicz, Tankanow, Vanderhoof, Gotz,
Adam). The study by Adam et al had the
biggest impact on the analysis yet is the
most suspect of all the trials, with only
19.4% of recruited cases being analysed, the
remainder being excluded because of
protocol violations.
Probiotics are not without risk, with over
11 case reports of Salmonella boulardii septi›
caemia in the literature. Uncritical reading
of this meta›analysis is misleading and risks
injudicious use of possibly ineffective, poten›
tially hazardous treatments. It may also
distract from proved interventions such as
modification of antibiotic policies.
John Beckly specialist registrar gastroenterology
(jbeckly@yahoo.com)
Stephen Lewis consultant gastroenterologist
(sjl@doctors.org.uk)
Derriford Hospital, Plymouth PL6 8DH
1 D’Souza AL, Rajkumar C, Cooke J, Bulpitt CJ. Probiotics in
prevention of antibiotic associated diarrhoea: meta›
analysis. BMJ 2002;324:1361›4. (8 June.)
2 Borgia M, Sepe N, Brancaro V, Simone P, Borgia R. Effect
of streptococcus lactic acid›producing bacteria (SF68
strain) on body weight in man: a double›blinded
controlled clinical study. Curr Ther Res 1983;33:214›8.
3 Colombel JF, Cortot A, Neut C, Romond C. Yoghurt with
Bifidobacterium longum reduces erythromycin›induced
gastrointestinal effects. Lancet 1987;ii:43.
Authors' reply
Editor—We agree with Battle et al that the
use of probiotics remains but one method of
manipulating faecal flora as a means of con›
trolling antibiotic induced diarrhoea. Using
lactulose is an interesting idea, although
altering bacterial flora by introducing an
organism that can colonise the bowel as well
as modify the proliferation of other organ›
isms seems easier. Probiotics also have an
antiendotoxin effect with an added benefit
of stimulating an immunoglobulin response
in the gut wall.1
Furthermore, the use of lactulose is lim›
ited by lack of knowledge on the optimum
dose at which it can have an effect on gut
flora while not causing diarrhoea.
We agree that Clostridium difficile
accounts for only 10›25% of cases of
antibiotic associated diarrhoea. It accounts,
however, for the most cases of colitis that
occur and remains treatable once diag›
nosed.2 Our recommendations on the use of
probiotics were not specific to elderly
people—we did point out that a trial was
needed in this age group.
The supposed error in table 1 relates to
the percentage free of diarrhoea in the
active and placebo groups in the study by
Gotz et al.3 Our analysis was performed by
using the numbers as mentioned (8.3% in
the active group v 21% in the placebo
group); the table highlighted the numbers in
the groups when other treatments likely to
induce diarrhoea were excluded.
The study by Borgia et al was excluded
because it primarily studied effects on body
weight.4 The study by Colombel et al did not
provide enough information on the number
of cases of diarrhoea alone (diarrhoea was
grouped as a side effect along with nausea,
vomiting and abdominal pain).5 We are criti›
cised for these exclusions and yet for includ›
ing studies analysed on a “per protocol”
basis, an acceptable scientifically rigorous
procedure.
We acknowledge the risks posed by pro›
biotics, but most complications occurred in
immunosuppressed individuals and people
with other life threatening illnesses. This was
mentioned in our paper, and we would leave
it to clinicians to decide the individual
suitability of patients to receive probiotics.
Our proposals about these agents seek
not to replace antibiotic and infection
control policies but to supplement them. A
Study Odds ratio
(95% CI)
Odds ratio
(95% CI)
Surawicz
McFarland
Lewis
Overall
(95% CI)
0.1 101
0.31 (0.07 to 1.36)
0.73 (0.16 to 3.37)
3.50 (0.35 to 35.44)
0.71 (0.29 to 1.76)
Weight
(%)
56.8
35.3
7.9
The effect of probiotics on antibiotic associated
diarrhoea
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multipronged approach should facilitate a
reduction in the occurrence of antibiotic
associated diarrhoea.
A L D’Souza research fellow
C Rajkumar senior lecturer
J Cooke statistician
C J Bulpitt professor of geriatric medicine
Care of the Elderly Section, Imperial College
Faculty of Medicine, Hammersmith Hospital,
London W12 0NN
1 Spanhaak S, Havenaar R, Schaafsma G. Effect of
consumption of milk fermented by Lactobacillus casei shi›
rota on intestinal microflora and immune parameters in
humans. Eur J Clin Nutrition 1998;52:899›907
2 Kelly CP, Pothoulakis C, LaMont JT. Clostridium difficile
colitis. N Engl J Med 1994;330:257›62.
3 Gotz V, Romankiewicz JA, Moss J, Murray HW. Prophylaxis
against ampicillin›associated diarrhoea with a lactobacillus
preparation. Am J Hosp Pharm 1979;36:754›7.
4 Borgia M, Sepe N, Brancaro V, Simone P, Borgia R. Effect
of streptococcus lactic acid›producing bacteria (SF68
strain) on body weight in man: a double blind controlled
study. Curr Ther Res 1983;33:214›8.
5 Colombel JF, Cortot A, Neut C, Romond C. Yogurt with
Bifidobacterium longum reduces erythromycin›induced
gastrointestinal effects. Lancet 1987;ii:43.
Metronidazole is used for
antibiotic associated diarrhoea
in pregnancy in UK
Editor—Barbut and Meynard quote US
guidance when recommending vancomycin
as first line treatment for antibiotic associ›
ated diarrhoea in pregnancy.1
In the United Kingdom guidance issued
by the medicines information centres and
the National Teratology Information Service
recommends metronidazole rather than
oral vancomycin after a careful risk assess›
ment of each drug.
Vancomycin is poorly absorbed from
normal, intact gastrointestinal mucosa, but
an inflammatory bowel process can result in
increased absorption of the oral product. In
patients with pseudomembranous colitis
vancomycin may occasionally reach thera›
peutic concentrations in serum, which can
theoretically damage a fetus’s VIIIth cranial
nerve.
In contrast, several epidemiological
studies in women have shown no conclusive
evidence that metronidazole causes an
increased risk of malformations, stillbirths,
or low birth weight.2–4 The accumulated data
on more than 1500 births with prenatal
exposure to metronidazole suggests no
increase in congenital anomalies.2–4
In addition, a retrospective cohort study
of nearly 1400 exposed pregnancies did not
detect an increase in infants with any of sev›
eral categories of congenital anomaly or low
birth weight. Analysis of data from the Hun›
garian case›control surveillance of congeni›
tal abnormalities between 1980 and 1991
found no association with congenital
anomalies among 266 pregnancies treated
with oral metronidazole during the first
trimester. A recent prospective controlled
study of 228 women exposed to metronida›
zole in pregnancy, 86% of whom were
exposed in the first trimester, confirmed
these findings.
The long term postnatal effects of
intrauterine exposure to metronidazole, if
any, have yet to be determined. However, data
from a 20 year ongoing study give no indica›
tion of an increased incidence of malig›
nancies after metronidazole treatment.5
Given the wide experience of metroni›
dazole in pregnancy and the theoretical
risks and less experience of using vancomy›
cin in pregnancy, the advice in the United
Kingdom is to use metronidazole 400 mg
thrice daily in preference to oral vancomy›
cin. It is used in the dosing schedule
(continuous or pulsed therapy) recom›
mended locally by microbiology depart›
ments and for the shortest time to clear the
infection.
Scott Pegler medicines information pharmacist
Morriston Hospital, Swansea NHS Trust, Swansea
SA6 6NL
scott.pegler@swansea›tr.wales.nhs.uk
Patricia McElhatton head
National Teratology Information Service, Regional
Drug and Therapeutics Centre, Wolfson Unit,
Newcastle upon Tyne NE2 4HH
1 Barbut F, Maynard JL. Managing antibiotic associated diar›
rhoea. BMJ 2002;324:1345›6. (8 June.)
2 Caro›Paton T, Carvajal A, Martin de Diego I, Martin›Arias
LH, Alvarez Requejo A, Rodriguez Pinella E. Is metronida›
zole teratogenic? A meta›analysis. Br J Clin Pharmacol
1997;44:179›82.
3 Morales WJ, Schorr S, Albritton J. Effect of metronidazole
in patients with preterm birth in preceding pregnancy and
bacterial vaginosis: a placebo›controlled, double›blind
study. Am J Obstet Gynecol 1994;171:345›9.
4 Garbis H, Reuvers M, Rost van Tonningen M. Anti›
infective agents. In: Schaefer C, ed. Drugs during pregnancy
and lactation. Amsterdam: Elsevier, 2001:58›84.
5 Beard CM, Noller KI, O’Fallon WM, Kurland LT, Dahlin
DC. Cancer after exposure to metronidazole. Mayo Clin
Proc 1988;63:147›53.
Heterogeneity among Indians,
Pakistanis, and Bangladeshis is
key to racial inequities
Editor—Feder et al recently confirmed and
extended observations pointing to inequity
in the invasive management of coronary dis›
ease.1 They conclude that the inequity is not
due to physician bias or socioeconomic sta›
tus and emphasise as explanations patients’
understanding of risks and benefits, and
barriers in the healthcare system after place›
ment on a waiting list.
Similar observations in the United States
have led to intense debate, particularly on
the potential role of racism. In my overview
on racism, which focused on the extensive
data on racial inequalities in treating heart
disease in the United States, I concluded that
the emerging, somewhat reluctant,
interpretation is that racism is important.2
Whittle et al included racism as a compo›
nent of the explanation for their findings in
a US study on the same theme.3 I also wrote
that even if patients’ preferences are partly
responsible for the disparities, racism will
not be wholly exonerated.2
Within the data of Feder et al are buried
important observations on heterogeneity
within the South Asian population that shed
light on the issue. For angioplasty, the deficit
of operations was only in Bangladeshis (haz›
ard ratio 0.23) and Pakistanis (0.34), and not
in Indians (1.22). In coronary artery bypass
grafting the deficit was greater in Bangla›
deshis (hazard ratio 0.56) and Pakistanis
(0.78) than in Indians (0.89).
Heterogeneity between Indians, Pakista›
nis, and Bangladeshis has been unequivo›
cally shown for socioeconomic circum›
stances and cardiovascular risk factors and
for degree of understanding about coronary
heart disease and diabetes.4 5 Incredible
though it may seem, in many respects
relevant to cardiovascular diseases, Indians
are closer to the reference “white” popula›
tion than they are to Bangladeshis. The cat›
egory Asian/South Asian, while of some
value, has pitfalls and can lead to false inter›
pretations and conclusions.
Such heterogeneity helps interpret
Feder et al’s work.
Firstly, we can conclude that crude
racism based on colour prejudice is not at
play.
Secondly, the factors at play are affecting
Bangladeshis most and Indians least. I am
not aware that Bangladeshis have different
attitudes to health care and to medical
advice, but they are comparatively poor, less
educated,4 uninformed about heart disease,5
and probably less well able to take advantage
of the NHS. Yet they have the worst profile
of cardiovascular risk factors and the highest
risk of disease.
In pursuit of the goal of healthcare
equity and acquiescence with the Race Rela›
tions Amendment Act 2000, the NHS will
need to adapt services to help ethnic minor›
ity populations overcome institutional barri›
ers, which may, unwittingly, disadvantage
them.2
Raj S Bhopal Bruce and John Usher professor of
public health
Public Health Sciences, University of Edinburgh,
Edinburgh EH8 9AG
raj.bhopal@es.ac.uk
1 Feder GG, Crook AM, Magee P, Banerjee S, Timmis A D,
Hemingway H. Ethnic differences in invasive management
of coronary disease: prospective cohort study of patients
undergoing angiography. BMJ 2002;324:511›6.
2 Bhopal RS. The spectre of racism in health and health
care: lessons from history and the United States. BMJ
1998;316:1970›3.
3 Whittle J, Conigliaro J, Good CB, Lofgren RP. Racial
differences in the use of invasive cardiovascular proce›
dures in the Department of Veterans Affairs medical
system. N Engl J Med 1993;329:621›7.
4 Bhopal RS, Unwin N, White M, Yallop J, Walker L, Alberti
KGMM, et al. Heterogeneity of coronary heart disease risk
factors in Indian, Pakistani, Bangladeshi, and European
origin populations: cross sectional study. BMJ
1999;319:215›20.
5 Rankin J, Bhopal R. Understanding of heart disease and
diabetes in a South Asian community: cross sectional study
testing the ‘snowball' sample method. Public Health
2001;115:253›60.
Sex differences in occupation
may affect height associations
Editor—Power et al use data from the
national child development study to show
that height is related to both social position
and social mobility.1 They also try to
measure the effect of changes in social struc›
ture on inequalities in height by comparing
two simple summary measures of the
relation of height to social class at age 7
(1965) and at age 33 (1991), separately for
men and women. They describe the
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differences in the social class distributions at
age 7 and 33 as changes in social structure
between 1965 and 1991 for parents and off›
spring at a comparable age in the life span.
For the men this is a fair comparison,
but it is potentially misleading for the
women. For both men and women social
class at age 7 is defined by the occupation of
their father. Comparing women’s occupa›
tions at 33 with their father’s at roughly the
same age is more complex as the compari›
son is confounded with sex differences in
occupation. These differences affect the
social class distribution and hence the meas›
ures of social inequalities.
The table gives the social class break›
down of 33 year old men and women from
the samples of anonymised records from
the 1991 census.2 It shows a close match to
the social class distributions of the subjects
in the national child develoment study at
age 33 in 1991, reinforcing their claim to
representativeness. It also shows the differ›
ences in social class distributions of men
and women.
These differences are particularly
noticeable for classes III non›manual and III
manual: women are much more likely to be
in class III non›manual than III manual, the
reverse being true for men. In the national
child development study 11% of women are
classified as III non›manual and 46% as III
manual at age 7, whereas at age 33, 37% are
in class III non›manual and 7% in III
manual.
These “changes” may be more appropri›
ately attributed to sex differences in occupa›
tion than to social mobility. Although there
may not be a “better” measure of social class
of origin available for the women, interpret›
ation of changes merits some caution.
Geoff Der statistician
Medical research Council Social and Public Health
Sciences Unit, Glasgow G12 8RZ
Geoff@msoc.mrc.gla.ac.uk
1 Power C, Manor O, Li L. Are inequalities in height under›
estimated by adult social position? Effects of changing
social structure and height selection in a cohort study.BMJ
2002;325:131›4. (20 July.)
2 Census Microdata Unit.A user’s guide to the SARs. Manches›
ter: University of Manchester, CMU, 1993.
Alcohol and death: the New
Zealand experience
Editor—As a simple measure of human
nature, I suspect the initial impact of the
paper by White et al on alcohol consump›
tion and mortality will depend on the age of
the reader1; as someone in the two unit a
week group (by a whisker of course) I was
drawn to read the article in more depth.
Although it is clear what the paper adds,
it is harder to decide how it affects what we
do as health professionals and as part of
society. The last comment made by the
authors in the discussion is particularly per›
tinent: “Finally, as most deaths attributable
to alcohol at younger ages are due to
injuries, a greater focus could be placed on
avoiding risky patterns of drinking rather
than on reducing average alcohol consump›
tion.”
Injuries are a significant cause of death
in young adults; even looking at all age
death rates given in table 1 in the paper, this
category is the third largest cause of death. It
would therefore be simplistic to respond to
this paper by reviewing recommended alco›
hol intake alone and ignoring behaviour.
Taking drink driving as an obvious example,
I have been interested to see the New
Zealand approach to this problem since
moving here from the United Kingdom.
Until recently, New Zealand had one of the
highest per capita death rates for road traffic
injuries in the world, and alcohol played a
large part in this (between 1987 and 1992,
35›46% of fatally injured drivers tested were
over the limit—two thirds to three quarters
were tested).2 Most of these alcohol related
deaths were in the age group 15›44 (peak
20›24 years), which reflects the risk findings
of the paper.
One of the strategies that has probably
helped to reduce this figure (20% of fatally
injured drivers in 2000) has been to vary the
legal alcohol limit by age. The legal limit
under the age of 20 years is 30 mg/100 ml
(blood)—this is effectively zero tolerance.
Penalties at all ages are high: financially,
through suspension, and through potential
custodial sentence. With alcohol as the
intervention and death as the outcome, one
of the key consequences of this paper
should be to continue to seek ways of mini›
mising or avoiding the processes that link
them together.
Andy M Wearn clinical senior lecturer
Faculty of Medical and Health Sciences, University
of Auckland, Auckland 1, New Zealand
a.wearn@auckland.ac.nz
1 White IR, Altmann DR, Nanchahal K. Alcohol consump›
tion and mortality: modelling risks for men and women at
different ages. BMJ 2002;325:191. (27 July.)
2 Land Transport Safety Authority. Blood alcohol limits.
www.ltsa.govt.nz/research/annual_statistics_2000/
blood_alcohol.html (accessed 17 September 2002).
Surveillance of whooping
cough should continue
Editor—Crowcroft and Britto’s editorial on
whooping cough gives little evidence of glo›
bal resurgence, mentioning only limited
outbreaks associated with strains producing
variants of pertactin and pertussis toxin and
no adverse role associated with variants
among British or French isolates.1 These two
components are virulence factors in mice,
but antibodies to them correlated poorly
with protection of children, and acellular
vaccines containing them have been less
efficacious than whole cell vaccine.2
Of more concern is the reliability of the
diagnosis of pertussis in some outbreaks of
coughing. Of 23 recently reported cases in
Leicestershire, only six had laboratory
confirmation, largely on the basis of tests of
less certain specificity (polymerase chain
reaction and serology) than positive culture.3
Culture confirmation rates of 80% can be
achieved by efficient pernasal swabbing and
meticulous laboratory procedures.4 Culture
negative cases, with a paroxysmal cough of
less than three weeks, may well be caused by
viruses or other microbes. With genuine
pertussis infection the organism has been
cultured while coughing persists for up to
three months from onset.4
The editorial suggests that vaccination
may be more effective in preventing disease
than infection. But, if the organism cannot
be cultured from mild infections in older
children and adults, these atypical cases are
unlikely to be a serious source of transmis›
sion. Moreover, this hypothesis is inconsist›
ent with the elimination of pertussis in
countries that have persisted with compul›
sory vaccination from 3 months of age with
whole cell vaccine containing all three
agglutinogens.5
Our own experience with British isolates
shows that in recent years the annual
incidence of culture confirmed cases has
been less than half that recorded in 1997,
with an appreciable fall in serotype 1,2.
Crowcroft and Britto are right to recall the
low efficacy of some vaccines in the 1970s
and 1980s in Canada and Sweden (and Fin›
land). If the vaccine was deficient in
agglutinogen 2, serotype 1,2 infection
occurred in vaccinated children. If the
vaccine was deficient in agglutinogen 3, type
1,3 infection occurred, but type 1,2 was
found also in non›vaccinated children
because of the colonising advantage of this
fimbriate serotype.5
We therefore support the call for contin›
ued surveillance. This should include thor›
ough attempts to obtain culture confirma›
tion of the infection, backed up by carefully
controlled serology in clinically suspected,
culture negative cases. The pertussis refer›
ence laboratory will continue to confirm the
identification and serotype of isolates
received and provide a serology service for
diagnosis and for assay of immune response
to vaccination.
Ruth C Matthews professor and director
Noel W Preston former director
Debbie J Holden research assistant
Pertussis Reference Laboratory, Central
Manchester Healthcare Trust, Manchester
M13 9WL
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Social class breakdown of men and women aged
33 in 1991. Values are percentages
Own social class Men Women
I 8.1 2.9
II 30.1 31.4
III non›manual 9.8 37.8
III manual 33.4 6.3
IV 13.6 16.2
V 4.9 5.4
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Adverse events with medical
devices may go unreported
Editor—Amoore and Ingram report that
400 people a year are seriously injured or
killed as a result of adverse incidents with
medical devices.1 We believe that this figure
is the tip of the iceberg and that many more
cases occur that are simply not recognised.
Infectious complications of medical devices
are often not considered in the context of
reporting, and so the possible lessons that
can minimise recurrence remain unlearnt.
One of the most commonly used
medical devices in hospital patients are per›
ipheral intravenous catheters. In our trust
alone 32% of all such patients have a
peripheral intravenous catheter in situ at any
one time. The risk of serious complications
associated with these devices is generally
perceived to be low. Over the past year, how›
ever, we have documented 19 cases of
Staphylococcus aureus bacteraemia resulting
from infection of such catheters.
Data from the Nosocomial Infection
National Surveillance Service (NINSS) sug›
gest that at least 7% of all nosocomial
bacteraemias are related to use of peripheral
intravenous catheters.2 A study of 146
catheters in our trust showed a serious com›
plication rate of 5.5%, a much higher rate
than that quoted in other studies in which
catheters are inserted by dedicated teams.3 4
We performed two studies of catheter
insertion and care to identify the factors
responsible for these complications. An
observational audit in emergency areas
showed that 63% of healthcare workers
made no attempt to decontaminate their
hands, and 13% failed to clean the skin
adequately before inserting peripheral intra›
venous catheters. Twenty per cent of all
catheters inserted and left in situ were not
used at all 48 hours later. A snapshot survey
of catheter care showed that a third of all
catheters were not in use, and 9% had never
been used since insertion. Sixty per cent of
all insertion sites were not visible, usually
because they were obscured by bandages.
Several simple measures have been
identified to reduce the risk of complications
occurring as a result of catheter insertion,
including the immediate removal of cath›
eters no longer in use, daily inspection of
insertion sites for local complications, and
the use of aseptic techniques when inserting
catheters.
Failure of medical equipment should
obviously be reported and action taken to
prevent adverse consequences. Yet failure of
simple good practice, leading to serious
complications of commonly used devices, is
not being addressed. The simple scheme
described by Amoore and Ingram needs to
be extended to encompass a wider range of
events, including infectious complications of
medical devices, so that these can be
highlighted.
Nicola Baker specialist registrar in microbiology
kendrin@heartsol.wmids.nhs.uk
Claire Tweedale infection control project nurse,
department of infection control
Chris J Ellis consultant physician, department of
infection and tropical medicine
Birmingham Heartlands Hospital, Birmingham
B9 5SS
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Bad bugs travel as well as
happy holidaymakers
Editor—Zuckerman’s timely article, coming
hot on the heels of Getting ahead of the curve,
should remind us of the personal risks
posed by tropical and imported infections.1 2
It should also remind us of the even greater
risks posed not only to individual patients
but also to the population as a whole by the
unevenness of availability of quality clinical
acumen across the United Kingdom when it
comes to diagnosing and managing this cat›
egory of illness.
Nowhere is this made clearer than by the
case of a 78 year old febrile woman who was
admitted to a British district general hospital
in December 1997.3 Subsequently she devel›
oped thrombocytopenia, melaena, and a
haemorrhagic rash. She died without a
diagnosis having been made, despite having
undergone numerous invasive investigations.
In retrospect, the key factor in her
history was that she had returned from Zim›
babwe a few days before admission. Zim›
babwe has Congo›Crimean haemorrhagic
fever, which therefore would—and should—
form part of the differential diagnosis in a
febrile patient. Congo›Crimean haemor›
rhagic fever was diagnosed postmortem in
this case.
Rare though cases of viral haemorrhagic
fever may be, the earliest possible recognition
of the possibility is crucial as there is great
potential for secondary spread. Congo›
Crimean haemorrhagic fever is associated
with severe haemorrhagic features—for
example, one case in a patient who was resus›
citated in a Saudi Arabian emergency unit
gave rise to seven secondary cases.4 The
possibility of a viral haemorrhagic fever
should accordingly result in expert bedside
clinical assessment and transfer to a category
4 isolation facility, as well as potentially life
saving ribavirin treatment in some cases.
On public and staff safety grounds
alone, therefore, the existence of this worry›
ing British case merits more widespread rec›
ognition. This is becoming especially and
increasingly important as tourism to Africa
and South America (where the bulk of the
most hazardous viral haemorrhagic fevers
are encountered) is increasing every year.
The new generation of double decker
“Super Jumbo” planes are each likely to be
able to carry 850 passengers rapidly across
vast distances, and it will only take one case
of viral haemorrhagic fever in any one of
these seats to lead to a major problem.
Coppetts Wood Hospital in London and
Newcastle General Hospital in Newcastle
upon Tyne are the only centres in the United
Kingdom that currently have adequate
category 4 facilities for managing not only
viral haemorrhagic fevers but also patients
potentially infected with highly transmissi›
ble biological agents used as weapons, such
as smallpox and pneumonic plague. Out of
almost 60 million people residing in the
United Kingdom, a densely populated
country, almost 50 million travel abroad
annually so two centres may in time prove to
be not enough.
Forewarned is forearmed—we should
take travel medicine and international
health issues seriously and be prepared.
Stephen T Green consultant physician
Royal Hallamshire Hospital, Sheffield S10 2JF
steve.green@sth.nhs.uk
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Correction
Don’t forget syphilis
An editorial error occurred in the second
letter of this cluster, by David Goldmeier and
Linda Greene (5 October, p 776). The first
sentence of the third paragraph should have
read: “Although treatment failures with one
injection of benzathine penicillin 2.4 MU in
patients with early syphilis and HIV have
been described,4 the latest guidelines from
the US Centers for Disease Control and
Prevention continue to advocate this one off
injection for HIV coexisting with syphilis.2”
[Not, as published: “Although treatment
with one injection of benzathine penicillin
2.4 MU in patients with early syphilis and
HIV has failed, the latest guidelines from the
US Centers for Disease Control and Preven›
tion continue to advocate this one off injec›
tion for HIV coexisting with syphilis.2 4”]
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